EQL Pharma ABOSTO:EQL -2.32%42 FCF Margin % is -0.36% as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, EQL Pharma AB ranks worse than 72.5% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. EQL Pharma AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-0.4 Mil. EQL Pharma AB's Revenue for the
three
months ended in Mar. 2026 was kr120.2 Mil. Therefore, EQL Pharma AB's FCF Margin % for the quarter that ended in Mar. 2026 was -0.36%.
The historical rank and industry rank for EQL Pharma AB's FCF Margin % or its related term are showing as below:
OSTO:EQL'
s FCF Margin % Range Over the Past 10 Years
Min: -72.42 Med: -18.13 Max: 4.82
Current: -9.1
During the past 13 years, the highest FCF Margin % of EQL Pharma AB was 4.82%. The lowest was -72.42%. And the median was -18.13%.
OSTO:EQL's FCF Margin % is ranked worse than 72.5% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs OSTO:EQL: -9.10
EQL Pharma AB FCF Margin % Related Terms
EQL Pharma AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a FCF Margin % of -0.36% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EQL Pharma AB and its competitors. According to the industry distribution chart, EQL Pharma AB ranks #696 out of 960 companies in the Drug Manufacturers industry, placing it in the top 72.5%.
Is EQL Pharma AB's FCF Margin % too high?
EQL Pharma AB's current FCF Margin % is -0.36%. Based on the distribution chart, EQL Pharma AB ranks #696 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #696 out of 960 companies for FCF Margin %. This places EQL Pharma AB in the lower half of its industry. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current FCF Margin % is -0.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current FCF Margin % of -0.36%. The current FCF Margin % is -0.36%. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current FCF Margin % is -0.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
